Cigna Group (CI) Resumen de Acciones
El Grupo Cigna, junto con sus filiales, ofrece seguros y productos y servicios relacionados en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 6/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 2/6 |
| Dividendos | 5/6 |
Recompensas
Análisis de riesgos
CI Community Fair Values
Create NarrativeSee what 96 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de The Cigna Group
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$282.02 |
| Máximo en las últimas 52 semanas | US$338.89 |
| Mínimo de 52 semanas | US$239.51 |
| Beta | 0.31 |
| Cambio en 1 mes | 1.93% |
| Variación en 3 meses | 0.61% |
| Cambio de 1 año | -9.81% |
| Variación en 3 años | 14.15% |
| Variación en 5 años | 8.68% |
| Variación desde la OPV | 4,757.76% |
Noticias y actualizaciones recientes
Seeking Alpha • May 18
Cigna: Shares Marching To Full Recovery
Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking AlphaArtículo de análisis • May 04
The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...
Actualización de narrativa • May 02
CI: Leadership Transition And Buybacks Will Support Future Share Upside
Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.Recent updates
Seeking Alpha • May 18
Cigna: Shares Marching To Full Recovery
Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking AlphaArtículo de análisis • May 04
The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...Actualización de narrativa • May 02
CI: Leadership Transition And Buybacks Will Support Future Share Upside
Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.Actualización de narrativa • Apr 17
CI: Leadership Transition And Buybacks Will Drive Future Upside
Analysts have trimmed their average price target on Cigna Group by about $0.38 to roughly $338.42, reflecting small updates to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Cigna Group plans a leadership transition, with current CEO David M.Actualización de narrativa • Apr 02
CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside
Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.Actualización de narrativa • Mar 19
CI: Onsite Care Expansion And Leadership Transition Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group from about $336.67 to roughly $338.80. This reflects updated views on revenue growth, profit margins, and an anticipated forward P/E of around 13.43x.Actualización de narrativa • Mar 05
CI: Onsite Care Expansion Will Support Future Upside Potential
Analysts now set Cigna Group's fair value estimate at about $336.67, up from roughly $332.62, reflecting updated assumptions that incorporate slightly higher revenue growth, profit margins, and a lower future P/E multiple. What's in the News Cigna Group plans a leadership transition, with CEO David M.Actualización de narrativa • Feb 19
CI: Higher Margin Outlook And Onsite Care Expansion Will Support Upside
Analysts have modestly lifted their price target on Cigna Group to $332.62 from $326.92, citing updated assumptions that combine slightly lower revenue growth with a higher profit margin and a future P/E of 15.62. What's in the News A class action lawsuit has been filed against Express Scripts, Cigna, and Evernorth, alleging a rebate diversion scheme that used an offshore entity, Ascent, to collect billions of dollars in kickbacks labeled as fees instead of passing rebates through to pharmacy benefit management clients, including the Plumbers' Welfare Fund.Actualización de narrativa • Feb 04
CI: Onsite Clinic And Stable Assumptions Will Support Future Upside
Analysts have kept their price target for The Cigna Group broadly unchanged at about US$327, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions rather than any major shift in their outlook. What's in the News Hankook Tire America Corp.Actualización de narrativa • Jan 21
CI: Completed Buybacks And New Employee Clinic Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group slightly higher to US$326.92 from US$325.57, citing minor refinements to discount rate assumptions, revenue growth expectations, profit margin inputs, and the forward P/E multiple used in their models. What's in the News Hankook Tire America Corp.Actualización de narrativa • Jan 07
CI: Massive Share Buyback And Clinic Expansion Will Support Future Earnings Upside
Analysts have slightly reduced their price target for Cigna Group, trimming fair value by about $0.69 to $325.57 as they factor in a more moderate revenue growth outlook, along with a small improvement in expected profit margins and future P/E assumptions. What's in the News Hankook Tire America Corp.Actualización de narrativa • Dec 15
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).Actualización de narrativa • Nov 30
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Analysts have raised their price target for Cigna Group to $328.35 per share, citing moderate adjustments to key financial metrics. These include a higher projected future price-to-earnings ratio and continued expectations for growth and profitability.Actualización de narrativa • Nov 16
CI: Significant Buybacks And 2026 Guidance Will Drive Upside Momentum
Narrative Update on Cigna Group Analysts have lowered their price target for Cigna Group from $349.04 to $328.35. This change reflects adjustments for a slightly higher discount rate as well as revised expectations for revenue growth and profit margins.Actualización de narrativa • Nov 01
CI: Share Repurchase Momentum Will Drive Long-Term Shareholder Value Creation
Analysts have lowered their price target for Cigna Group from $369.13 to $349.04. This change reflects updated expectations around modestly higher revenue growth, which are offset by a slight dip in profit margin projections.Artículo de análisis • Jul 10
The Cigna Group (NYSE:CI) Screens Well But There Might Be A Catch
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Artículo de análisis • Jun 19
These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Mar 31
The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price
Summary Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth. With an attractive valuation and minimal downside risk, Cigna stock is rated a BUY, offering at least 33% upside potential even in bearish conditions. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Cigna Is A Buy: Market Overreaction Creates A Big Opportunity
Summary Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings per share and investor returns. Regulatory risks, rising costs, and competition remain challenges to watch. If Cigna meets its targets, the stock could rise 20-30% from here. Read the full article on Seeking AlphaSeeking Alpha • Jan 18
Cigna: Buy The Drop On This Undervalued Growth Stock
Summary Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks. CI's growing dividend and robust fundamentals make it an attractive choice for value and growth investors, despite potential regulatory and macroeconomic risks. Read the full article on Seeking AlphaSeeking Alpha • Dec 13
Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share
Summary Cigna faces significant risks due to potential healthcare reforms and scrutiny on PBMs, making it a "Hold" until it drops below $230/share. The US healthcare system's high costs and structural issues contribute to the uncertainty surrounding Cigna's long-term profitability and business model. Despite strong historical performance, the potential breakup of PBMs and legislative changes could drastically impact Cigna's future earnings and growth. The current valuation does not justify investment; Cigna's appeal lies in its fundamental strengths but is overshadowed by systemic risks and political uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Sep 26
Cigna: This Dividend Grower Could Be Worth Buying Now
Summary The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value. Cigna could be set up to generate strong total returns in the next couple of years. Read the full article on Seeking AlphaSeeking Alpha • Sep 19
Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth. Despite low operating margins and elevated cost trends, Cigna's share repurchase program and SG&A optimization are expected to support future margin expansion and free cash flow growth. Read the full article on Seeking AlphaSeeking Alpha • Jul 29
Cigna Group: Services Focus Leads To Outperformance
Summary Cigna Group's medical memberships are focused on "services-only" commercial memberships. The fee-based rather than risk-based nature of these memberships makes Cigna more resilient to rising medical costs. The Evernorth segment should see high-single-digit growth for the foreseeable future, driven by Healthcare Services and specialty pharmacy Accredo. The low valuation coupled with the mid-single-digit earnings growth outlook makes Cigna stock attractive at current prices. Read the full article on Seeking AlphaSeeking Alpha • Jul 12
Cigna: Game Over For PBMs?
Summary Pharmacy Benefit Managers are increasingly in the spotlight of regulators and the media, potentially leading to government intervention. Express Scripts, Cigna's PBM, is responsible for nearly 75% of the company's revenue, which raises the question of whether CI stock is still a safe investment. This article discusses the potential implications in a scenario-based approach, focusing on segment profit, consolidated profit, dividend safety, and valuation. In addition, I share my thoughts on the recent opioid litigation in Arkansas and explain why I continue to sleep well with my investment in Cigna. Read the full article on Seeking AlphaRentabilidad de los accionistas
| CI | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | -4.4% | -2.8% | -0.8% |
| 1Y | -9.8% | 14.6% | 27.1% |
Rentabilidad vs. Industria: Los resultados de CI fueron inferiores a los de la industria US Healthcare, que obtuvo un rendimiento del 14.6% el año pasado.
Rentabilidad vs. Mercado: CI obtuvo unos resultados inferiores a los del mercado US, que fueron del 27.1% el año pasado.
Volatilidad de los precios
| CI volatility | |
|---|---|
| CI Average Weekly Movement | 3.8% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: CI no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CI (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1792 | 66,685 | David Cordani | www.thecignagroup.com |
El Grupo Cigna, junto con sus filiales, ofrece seguros y productos y servicios relacionados en Estados Unidos. Opera a través de dos segmentos: Evernorth Health Services y Cigna Healthcare. El segmento Evernorth Health Services incluye Pharmacy Benefit Services y Specialty and Care Services, que ofrecen gestión de beneficios farmacéuticos, adjudicación de reclamaciones de medicamentos, administración de redes de farmacias minoristas, consulta de diseño de beneficios, revisión de utilización de medicamentos, gestión de formularios de medicamentos, beneficios farmacéuticos, farmacia a domicilio, farmacia especializada, distribución de especialidades farmacéuticas y programas clínicos para obtener resultados de salud integral de la persona.
Resumen de fundamentos de The Cigna Group
| Estadísticas fundamentales de CI | |
|---|---|
| Capitalización bursátil | US$74.89b |
| Beneficios(TTM) | US$6.29b |
| Ingresos (TTM) | US$277.89b |
11.9x
Ratio precio-beneficio (PE)0.3x
Ratio precio-ventas (PS)¿Está CI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CI | |
|---|---|
| Ingresos | US$277.89b |
| Coste de los ingresos | US$252.47b |
| Beneficio bruto | US$25.42b |
| Otros gastos | US$19.14b |
| Beneficios | US$6.29b |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 30, 2026
| Beneficios por acción (BPA) | 23.77 |
| Margen bruto | 9.15% |
| Margen de beneficio neto | 2.26% |
| Ratio deuda/patrimonio | 72.8% |
¿Cómo se ha desempeñado CI a largo plazo?
Ver rendimiento histórico y comparativaDividendos
2.2%
Rentabilidad actual por dividendo26%
Ratio de pagos¿Paga CI dividendos fiables?
Ver historial de dividendos e índices de referencia de CI| fechas de dividendos de Cigna Group | |
|---|---|
| Fecha ex dividendo | Jun 04 2026 |
| Fecha de pago de dividendos | Jun 18 2026 |
| Días hasta ex dividendo | 13 days |
| Días hasta la fecha de pago de dividendos | 27 days |
¿Paga CI dividendos fiables?
Ver historial de dividendos e índices de referencia de CIAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 11:58 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
The Cigna Group está cubierta por 40 analistas. 17 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |